Henlius

#HenliusinFocus We’re pleased to announce a new strategic collaboration with Eisai Co., Ltd. for the exclusive commercialization of our innovative #PD1 inhibitor serplulimab (trade name: Hetronifly® in Europe) in Japan. With a differentiated binding profile and growing global clinical validation, serplulimab has already been approved across multiple tumor types in China and the EU. Under this agreement, we aim to accelerate access in Japan to serplulimab for patients with extensive-stage small cell lung cancer (ES-#SCLC), non–MSI-High metastatic colorectal cancer (#mCRC), and other high unmet-need indications. This partnership marks another meaningful step in Henlius’ Globalization 2.0 journey—combining our innovation capabilities with strong local expertise to bring differentiated immunotherapies to patients who need them most. We look forward to working closely with Eisai to advance patient-centered #CancerCare in Japan. Learn more: https://lnkd.in/gbEqCm7D

#WorldCancerDay 2026 | United by Unique Cancer affects every individual differently — yet we are united by a shared commitment to confront it, together. Each year, more than 20 million people worldwide are newly diagnosed with cancer. Behind every number is a life, a family, and a journey that deserves better answers and better options. At Henlius, we are guided by a patient-centric mindset, advancing a diversified #oncology pipeline across #LungCancer, #BreastCancer, #GICancers, hematologic malignancies and more. By continuously exploring innovative mechanisms and combination strategies, we aim to expand the clinical value of cancer treatment across different disease stages and patient populations. On this World Cancer Day, we stand with patients, caregivers, clinicians and partners around the world — united by science, compassion, and the shared hope of improving outcomes for people living with cancer. 💜 #UnitedbyUnique. Together against cancer.

During #JPM2026, our CEO Jason Zhu MD PhD sat down with Fierce Biotech to share how Henlius is navigating long-term growth in a changing global #biotech landscape. In the interview, Jason discusses: • what makes Henlius' business model distinctive in the global biotech landscape • as one of the first profitable Chinese biotech companies from product sales, while continuing to invest heavily in innovation, how does Henlius balance between R&D investment and commercial returns • how global clinical, regulatory and manufacturing capabilities are becoming true competitive advantages As Fierce Biotech noted, Henlius represents a new generation of China-origin biopharma companies advancing with scale, quality and global execution. We appreciate the opportunity to share our journey — and the ongoing dialogue with global industry peers. 🔗 https://lnkd.in/gzvSFzAe 🎥 Watch the full interview below

Recently in San Francisco, investigators from more than 20 U.S. clinical sites came together to align on the Phase 3 HLX22-GC-301, a head-to-head trial evaluating HLX22, a differentiated HER2-targeted strategy versus standard of care (± pembrolizumab) in first-line HER2-positive gastric and GEJ cancers. HLX22 is designed to deepen HER2 blockade beyond current approaches, with the goal of translating more complete target inhibition into more meaningful and durable clinical benefit for patients, when combined with trastuzumab and chemotherapy. We are grateful for the leadership and insights of our global investigator community, including Dr. Jaffer A. Ajani (MD Anderson Cancer Center) and Dr. Yelena Janjigian (Memorial Sloan Kettering Cancer Center), whose continued collaboration is critical to advancing this trial with scientific rigor and patient focus. With HLX22-GC-301 now enrolling across multiple countries and regions, including China, the United States, Japan, Australia, and Latin America, we remain committed to advancing the treatment landscape of #GastricCancer — working with the global clinical community to explore new options that may meaningfully improve outcomes for patients worldwide. Learn more: https://lnkd.in/giyZqtuZ

Thrilled to share that Henlius was highlighted by Swiss broadcaster SRF - Schweizer Radio und Fernsehen in their 10vor10 program. The piece underscores that China's #biotech momentum is real, and it's shaping the global conversation. The segment zoomed in on our labs in Shanghai, tracing our path from biosimilars to innovative assets on oncology, with a clear strategy to bring high-quality therapies to the global market. As SRF News reported, "reaching the world’s top tier appears to be only a matter of time for Chinese pharmaceutical companies." We’re grateful for the recognition and more motivated than ever to keep pushing forward — turning science into health, for patients everywhere.

A new clinical trial application has been approved in China to evaluate HLX43, a potential best-in-class PD-L1 ADC, in combination with serplulimab (anti-PD-1 mAb) and HLX07 (anti-EGFR mAb) for advanced solid tumors. As immune checkpoint inhibitors have become a cornerstone of cancer therapy, many patients still experience limited benefit from single-agent approaches. Combining #ImmunoOncology, #ADC and #TargetedTherapy offers the potential to deepen responses and address resistance through complementary mechanisms, aiming to unlock broader and more durable benefit across multiple tumor types. At Henlius, we continue to explore science-driven strategies to expand what’s possible for patients. Learn more: https://lnkd.in/gwigeJmJ

Henlius’ next-generation SIRPα-Fc #FusionProtein HLX701 has advanced into a Phase 1b/2 combination trial in advanced RAS/BRAF wild-type #ColorectalCancer, exploring how innate and adaptive immunity can work better together. With encouraging preclinical and early clinical signals across multiple tumor models, HLX701 is being developed as a potential #immunotherapy backbone that could synergize with existing checkpoint inhibitors, ADCs and targeted therapies. We are more than excited to see this next-gen immunotherapy bring new hope to patients with unmet needs in the future. Learn more: https://lnkd.in/gvpwnM_A

#HenliusMedicalHub We are proud to see serplulimab contribute to meaningful advances for patients with esophageal squamous cell carcinoma (#ESCC). Results from a Phase 2 investigator-initiated study of serplulimab in neoadjuvant treatment of resectable, locally advanced ESCC have been published in #NatureCommunications, reporting a 31.1% pCR rate, strong disease control and a favorable safety profile. Through advanced spatial proteomics, the study also revealed tumor microenvironment features linked to treatment response and resistance — helping move #immunotherapy toward more precise, patient-centered strategies. This publication reflects not only the dedication of Chinese investigators, but also Henlius’ commitment to enabling globally impactful, science-driven innovation, and innovation grows where science, clinicians and patients meet.

#HenliusinFocus #JPM2026 was an important moment for Henlius to share our Globalization 2.0 journey — and what it takes to build a sustainable global biopharma company. As our CEO Jason Zhu MD PhD shared: “Leveraging our integrated R&D, regulatory and manufacturing capabilities, together with an increasingly mature global clinical and commercialization network, we have established a systematic capacity to continuously deliver innovative assets worldwide. Over the next five years, stable cash flows from our biosimilar portfolio will further support innovation investment, enabling the advancement of more differentiated molecules, including ADCs, multi-Abs and TCEs, into global markets and building a sustainable, replicable globalization growth model.” From differentiated innovative assets to next-generation platforms, from clinical operations to global commercialization — every step is guided by one purpose: to bring meaningful innovation to more patients, worldwide. Thank you to everyone who connected with us at JPM 2026. We look forward to what’s ahead. Missed the session? Listen to the replay (available for up to 30 days following the presentation): https://lnkd.in/gb5GZXW4 Learn more: https://lnkd.in/gXAZCdfw

#HenliusinFocus At #JPM2026, we took another step in expanding our innovation beyond oncology — toward areas of significant unmet need in #autoimmune and inflammatory diseases. By licensing-in a best-in-class–potential anti–IL-1RAP mAb from U-mab Biopharma, Henlius is advancing a strategy focused on addressing #inflammation at its source. Targeting IL-1RAP enables simultaneous blockade of multiple IL-1 family pathways, offering a differentiated approach for diseases where current single-cytokine therapies remain insufficient. This collaboration reflects our long-term commitment to building a diversified, science-driven innovation ecosystem — spanning oncology, autoimmune, and inflammatory diseases — with the shared goal of delivering more effective and accessible treatment options for patients worldwide. We look forward to progressing this asset and continuing to translate frontier biology into meaningful patient impact. Learn more: https://lnkd.in/gcGAykuE